A Study on the Correlation Between MDR1 Polymorphism and Clopidogrel Resistance in Hui Patients Treated with Percutaneous Coronary Intervention

References

• Liu YM, Liu NF. Advances in clinical and genetic studies of clopidogrel response variability. Chin J Cardiovasc Dis. 2010;38:759–762.
   Google Scholar
• Juliao RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Pharmacogenomics. 2011;12:114–144.
   Google Scholar
• Barragan P, Bouvier JL, Roqu Ebert PO. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003;59(3):295–302. doi:10.1002/ccd.10497
   PubMed Web of Science ®Google Scholar
• Bliden KP, Di CJ, Tantry US. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current anti-platelet therapy adequate? J Am Coll Cardio. 2007;49(6):657–666. doi:10.1016/j.jacc.2006.10.050
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375. doi:10.1056/NEJMoa0808227
   PubMed Web of Science ®Google Scholar
• Zhou TT. Current status of clopidogrel and gene polymorphism. Chin J Clin Pharm. 2017;13:110–113.
   Google Scholar
• Gutierrez-Rubio SA, Quintero-Ramos A, Durán-Cárdenas A. 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res. 2015;14(1):1250–1259. doi:10.4238/2015.February.13.3
   PubMed Web of Science ®Google Scholar
• Bai XC, Liu M. To investigate the effect of clopidogrel resistance on the prognosis of elderly patients with acute coronary syndrome undergoing coronary intervention. Chin J Mod Drug Appl. 2018;23:89–90.
   Google Scholar
• Karaźniewicz-Łada M, Danielak D, Rubiś B, et al. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther. 2015;40(2):226–231. doi:10.1111/jcpt.12236
   PubMed Web of Science ®Google Scholar
• Chen F. Clinical study on cytochrome P4502C19*2 gene polymorphism and clopidogrel resistance and recurrent cardiovascular events. Taiyuan: Second Clinical Medical College of Shanxi Medical University; 2014.
   Google Scholar
• Su J Association between ABCB1 gene polymorphism and clopidogrel resistance; 2014.
   Google Scholar
• Qiu XY, Jiao Z, Zhong LJ. Effects of MDR1 C1236T, G2677T/A and C3435T gene polymorphisms on cyclosporine pharmacokinetics in Chinese Han renal transplant patients. Chin J Clin Pharm. 2008;17:141–146.
   Google Scholar
• Mega JL, Close SL, Wiviott SD. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312–1319. doi:10.1016/S0140-6736(10)61273-1
   PubMed Web of Science ®Google Scholar
• Wei HJ, Shi JT, Li XX, et al. Antiplatelet drug efficacy in clopidogrel-resistant patients after coronary stenting. J Clin Exp Med. 2017;16:79–82.
   Google Scholar
• Bonello L, De Labriolle A, Scheinowitz M, et al. Emergence of the concept of platelet reactivity monitoring of response to thienopyridine. Heart. 2009;95(15):1214–1219. doi:10.1136/hrt.2008.152660
   PubMed Web of Science ®Google Scholar
• Sun W, Li Y, Li J. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets. 2015;26(6):558–562. doi:10.3109/09537104.2014.953044
   PubMed Web of Science ®Google Scholar
• Li HP. Association between CYP2C19 gene polymorphism and clopidogrel resistance. Tianjin: Graduate School of Tianjin Medical University; 2013.
   Google Scholar
• Kim RB, Leake BF. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–199. doi:10.1067/mcp.2001.117412
   PubMed Web of Science ®Google Scholar
• Li YH, Wang YH. MDR1 gene polymorphisms and clinical relevance. Acta Genet Sin. 2006;33(2):93–104. doi:10.1016/S0379-4172(06)60027-9
   Google Scholar
• Pedersen RS, Nielsen F, Stage TB. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Clin Exp Pharmacol Physiol. 2014;41(11):870–878. doi:10.1111/1440-1681.12297
   PubMed Web of Science ®Google Scholar
• Li Y, Tang HL, Hu YF. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2012;10(2):199–206. doi:10.1111/j.1538-7836.2011.04570.x
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512–518. doi:10.1161/CIRCULATIONAHA.109.885194
   PubMed Web of Science ®Google Scholar
• Tiroch KA, Sibbing D, Koch W. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160(3):506–512. doi:10.1016/j.ahj.2010.06.039
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Knight S, Horne BD. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modifi ed by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost. 2013;109(04):744–754. doi:10.1160/TH12-05-0336
   PubMed Web of Science ®Google Scholar
• Pare G, Mehta SR, Yusuf S. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704–1714. doi:10.1056/NEJMoa1008410
   PubMed Web of Science ®Google Scholar